Dopamine receptor D3 subtype (DRD3)

Dopamine receptor D3 subtype (DRD3) is a G protein-coupled receptor primarily expressed in the brain's limbic regions (e.g., nucleus accumbens, olfactory tubercle, islands of Calleja), mediating many of dopamine’s effects on emotion, motivation, cognition, and reward behavior[1][3][5][7]. It belongs to the D2-like family of dopamine receptors and primarily signals through Gi/Go proteins to inhibit adenylyl cyclase, leading to decreased intracellular cAMP[1][6]. DRD3 plays a key regulatory role in tonic dopamine signaling, modulates neural excitability by controlling voltage-gated calcium channels, and acts as an autoreceptor to inhibit dopamine release (notably in the prefrontal cortex)[1][3]. Preclinical and clinical studies have implicated D3 receptors in Parkinson’s disease (as a therapeutic target of several agonists), schizophrenia and other mood disorders (with altered DRD3 signaling or as targets of antipsychotics and partial agonists like cariprazine), as well as in addiction, where D3 antagonists may reduce drug-seeking behaviors[1][3][7]. Safety issues for D3-modulating drugs include risk of typical dopaminergic side effects (such as impulse control disorders or psychosis with agonists)[1][3]. The receptor is encoded by the DRD3 gene on chromosome 3q13.3[1][6].

Other names

Dopamine D3 receptorDRD3

Agonists (stimulate the receptor to reduce motor symptoms in Parkinson’s disease); Antagonists (block receptor to reduce drug-seeking behavior/addiction); Partial agonists (modulate circuits related to negative symptoms in schizophrenia and mood disorders); Inhibition of adenylyl cyclase via Gi/Go coupling